Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Endothelial Barriers and Vascular Function: Full Study

Previous related pageVitamin D, Endothelial Barriers and Vascular Function: Study SummaryNext related pageFrom Endothelial Signals to Smooth-Muscle Tone
Study at a glance

Can vitamin D-related treatments change how blood vessels work?

The endothelium is the thin cell layer lining blood vessels. Researchers tested whether vitamin D-related treatments affect leakage through this layer or the ability of vessels to widen. These are different functions. Experiments in rats and human cells grown in the laboratory used paricalcitol, a drug similar to active vitamin D. Separate trials in people used vitamin D2 supplements.

Did an active vitamin D-like drug reduce leakage in laboratory tests?

Paricalcitol reduced leakage through the aorta’s lining in rats with experimentally caused kidney disease. A vitamin D-deficient diet alone did not significantly change the leakage result. In cells grown in the laboratory, the higher tested drug concentration strengthened the barrier and helped it resist disruption. The lower concentration did not show a significant improvement in the barrier before disruption. These findings do not measure heart blood flow or demonstrate prevention of heart attacks.

Did vitamin D2 improve blood-vessel responses in people?

An exploratory six-month trial assigned 38 adults with kidney disease and low vitamin D to vitamin D2 or placebo. One test of small blood vessels in the skin improved, but other vessel measurements did not improve consistently. The trial recruited fewer people than planned and had incomplete follow-up. A separate eight-week trial assigned 93 overweight or obese adults without high blood pressure or established heart disease. Vitamin D2 raised blood vitamin D but did not significantly improve widening of the upper-arm artery compared with placebo.

Do these studies show that vitamin D protects heart health?

The studies used different compounds, participants and tests, so they do not measure the same effect. Animal and cell findings can suggest how a treatment might work, but cannot establish a benefit in people. The human trials do not prove that every possible effect is absent. Together, these studies do not establish a supplement dose, blood target or prevention of heart and circulation problems.

Read the full article below ↓

Can vitamin D signalling help endothelial cells maintain a barrier, and does this mean supplements improve vascular function in people? The experiments examined here measure different parts of that question. A 2018 study tested a vitamin D analogue in rats with kidney disease and in cultured human endothelial cells. Two human trials provide separate evidence about stimulated blood-vessel responses. For the shorter account, read Vitamin D, Endothelial Barriers and Vascular Function: Study Summary.

Barrier integrity and vessel relaxation are different outcomes

The endothelium is the cell layer lining blood vessels. Its functions include regulating passage across the vessel wall and communicating with the surrounding muscle. The endothelial function overview explains this wider setting. An experiment showing less leakage across a cell layer does not, by that result alone, show that an artery relaxes more readily or delivers more blood to an organ.

This distinction also clarifies the connection with heart physiology. The heart pumps into a vascular system whose lining, muscular wall and circulating signals interact. Yet a measurement in the rat aorta or a dish of umbilical-vein cells is not a measurement of coronary blood flow or cardiac pumping. Each preparation answers a narrower question.

The principal barrier experiment used paricalcitol, a synthetic active vitamin D analogue. It did not give ordinary vitamin D3 supplements to patients. Background on vitamin D receptors helps distinguish activation of a signalling system from the amount of nutritional vitamin D entering that system. The form of the compound, its concentration and the experimental setting are essential to interpreting the result.

How the rat experiment separated kidney disease, diet and treatment

Vila Cuenca and colleagues studied male Wistar rats. They induced chronic kidney disease by removing one kidney and reducing blood supply to part of the other, leaving approximately one quarter of the original renal capacity. Thirty-two rats underwent the procedure and four died during surgery. The remaining kidney-disease animals were distributed across four experimental groups. Healthy controls did not undergo a sham operation.

The complete design contained eight groups, with six to eight animals allocated to each: kidney disease or no kidney disease, standard or vitamin D-deficient diet, and paricalcitol or vehicle. Some endpoint analyses used fewer animals. This factorial arrangement could examine whether an effect depended on kidney disease, low vitamin D availability or their combination. It was more informative than comparing only one deficient group with one treated group.

Vitamin D deficiency was induced over weeks 1-4 and the deficient diet continued to week 11. The induction procedure also used short-term injected paricalcitol to accelerate vitamin D breakdown. That preparatory manipulation must be distinguished from the later treatment comparison. During the seven-week treatment phase, rats received oral paricalcitol at 0.1 micrograms/kg three times weekly, or the sugar-water vehicle. These are experimental exposures, not instructions for human supplementation.

Urea and creatinine measurements supported the establishment of kidney dysfunction, and circulating vitamin D measurements assessed the dietary manipulation. The supplementary analyses also measured parathyroid hormone. These checks matter because kidney disease alters several interacting hormonal systems. The wider calcium physiology pathway provides context for those mineral and hormone relationships, but the vascular endpoint here remained a direct measure of barrier leakage.

What the aortic leakage and tissue measurements showed

The researchers injected Evans Blue dye, collected the thoracic aorta after 30 minutes and measured retained dye. They corrected the tissue measurement for tissue weight and circulating dye concentration. More dye in the vessel wall indicated greater passage across the endothelial barrier under the test conditions. This was not a measurement of total blood flow or the diameter of the artery.

Kidney disease increased the leakage signal by about 53% in untreated animals on the standard diet. Paricalcitol attenuated this effect, and analysis supported a surgery-by-treatment interaction. In the reported model, the treatment term had P=0.021 and the interaction P=0.012. Vitamin D-deficient diet did not significantly modify leakage in this experiment. The result therefore does not support a simple claim that dietary deficiency alone caused the measured barrier defect.

Tissue staining supplied a complementary observation. CD31, an endothelial marker, helped identify discontinuities in the aortic lining. Kidney-disease animals had more gaps, and treated animals had fewer. Agreement between dye passage and tissue appearance strengthens the interpretation that barrier integrity changed. It still does not identify every molecular step responsible for that change.

Several limits remain. The surgical model produces a particular form of kidney dysfunction, and the absence of sham surgery leaves the healthy comparison less tightly controlled for the operation itself. Groups were small, animals were male, and the study did not measure cardiovascular events. The paper does not establish that the same exposure would repair the endothelium of patients with kidney disease.

Human cells: junctions, electrical resistance and recovery

The cell experiments used human umbilical-vein endothelial cells from healthy donors, at early culture passages. They were not cells taken from the adult kidney-disease trial participants. Cells were exposed for 24 hours to paricalcitol at 10 or 100 nanomoles/litre, with vehicle and a separate α-Klotho comparison. α-Klotho is a kidney-associated protein that was investigated as a possible contributor to the vascular effects.

Electrical impedance measurements tracked resistance across the cell layer. Greater resistance in this assay is consistent with a tighter barrier, although it is an experimental proxy rather than a direct measure of clinical vascular health. At 100 nanomoles/litre, paricalcitol increased baseline resistance by about 8.4%. The smaller increase at 10 nanomoles/litre was not statistically significant. It would be inaccurate to describe every tested concentration as producing an established baseline effect.

Microscopy showed greater junctional VE-cadherin staining and changes in the actin framework around the cells. VE-cadherin helps neighbouring endothelial cells attach to one another; actin contributes to cell shape and tension. Together, these observations offer a structural explanation for a stronger cell barrier. They do not prove that one protein alone mediated the electrical-resistance result. The displayed experiments were based on cells from three donors, not a large patient sample.

The investigators also challenged the cell layer with thrombin, a clotting enzyme used here to disrupt endothelial contacts. After one hour, resistance had fallen by approximately 45% in control cells, compared with 35% after the higher paricalcitol exposure and 38% after the lower exposure. These are percentage drops from each group’s baseline. A drop of 35% rather than 45% is a difference of about ten percentage points, not a 35% improvement.

A separate electrical-wounding experiment assessed how the layer recovered after local injury. Paricalcitol accelerated recovery in the measured resistance trace. That result concerns repair in a simplified culture system. It does not demonstrate faster wound healing in a person, reduced plaque rupture or protection against a heart attack. Keeping the outcome attached to its preparation prevents the word “repair” from becoming broader than the evidence.

What the α-Klotho results can and cannot explain

Kidney disease reduced α-Klotho expression and circulating levels. Paricalcitol did not significantly restore the measured kidney expression or circulating concentration in the principal analyses. The supplementary immunoblot supported the kidney-protein assessment. These findings argue against a large measured restoration of α-Klotho being necessary to accompany the observed barrier response in this experiment.

They do not exclude every contribution from α-Klotho, local signalling or unmeasured systemic changes. A nonsignificant concentration difference is not proof that a pathway has no role. Likewise, the isolated-cell result supports the possibility of a direct endothelial effect but cannot establish the exact contribution of that effect within a whole animal. The study received support from AbbVie, which supplied paricalcitol, and disclosed relevant author relationships; those disclosures belong alongside its design strengths and limits.

A human kidney-disease trial measured a different function

Dreyer and colleagues randomised 38 adults with non-diabetic stage 3-4 chronic kidney disease and 25-hydroxyvitamin D below 16 ng/mL to ergocalciferol, vitamin D2, or placebo. Twenty received vitamin D2 and eighteen placebo. Treatment was 50,000 IU weekly for four weeks, then monthly for five months. Participants and investigators were blinded. This tested nutritional replacement over six months, unlike the active analogue used in the barrier experiment.

A laser Doppler instrument measured forearm skin microvascular responses while a small electrical current delivered acetylcholine through the skin. Acetylcholine tests a response that depends substantially on endothelial signalling. Sodium nitroprusside provided a separate, endothelium-independent vasodilator comparison. The outcome was the increase in local laser Doppler flux relative to baseline, not litres of blood delivered to the heart or kidneys.

The acetylcholine response favoured vitamin D2 over time, with P=0.03 in the repeated-measures analysis and P=0.012 for the six-month comparison. Mean stimulus-evoked increases in flux were 964.8% and 785.9% at baseline in the vitamin D2 and placebo groups, respectively, and 1130.0% and 540.6% at six months. These large percentages describe the response relative to resting skin flux, not a comparable increase in overall blood circulation. The nitroprusside response did not show a significant treatment effect. Other vascular measurements did not move uniformly: aortic pulse-wave velocity and sublingual microcirculatory measurements did not show corresponding improvement. A positive result in one vascular test cannot be expanded into improvement in every vascular compartment.

This was an exploratory single-centre trial. The protocol planned 80 participants and listed several vascular endpoints, while the publication enrolled 38 and emphasised the acetylcholine response. That history warrants caution about statistical power, multiple outcomes and endpoint emphasis. Two treated participants and one placebo participant were lost to follow-up; other participants had only three-month data before study closure. The complete six-month comparison therefore involved fewer people than the randomised total.

Separate cultured aortic-cell experiments in the same publication found increased endothelial nitric oxide synthase expression after ergocalciferol exposure. They offer a possible mechanistic connection, not proof that this pathway caused the patient response. The study was too small and short to determine cardiovascular-event prevention. Its positive microvascular finding remains a specific result requiring confirmation.

Why a second human trial did not show the same benefit

Borgi and colleagues randomised 93 overweight or obese adults with low vitamin D status but without hypertension or established cardiovascular disease. Eighty-four completed the eight-week trial. Weekly 50,000 IU ergocalciferol raised vitamin D concentrations but did not significantly improve brachial-artery endothelial-dependent vasodilation compared with placebo.

Vasodilation was measured as the percentage change in brachial-artery diameter during increased flow after five minutes of temporary ischaemia. Mean vasodilation changed from 6.3% to 6.1% with vitamin D2 and from 7.9% to 6.8% with placebo; the between-group comparison of change gave P=0.35. The journal subsequently replaced Figure 3 in an erratum. The comparison quoted here comes from the article’s numerical results. This short trial does not establish equivalence or exclude every possible effect in other populations. It does show that correcting low status did not reliably improve this measured outcome under these conditions.

How to read the studies together

Study settingIntervention and outcomeSupported interpretation
Rats and cultured human endothelial cellsParicalcitol; leakage, junctions and resistanceEvidence for barrier stabilisation in these models
Adults with chronic kidney diseaseVitamin D2; skin response to acetylcholineA positive exploratory microvascular result
Overweight or obese adults without hypertensionVitamin D2; brachial-artery vasodilationNo significant benefit over placebo in eight weeks

These findings are not interchangeable replications. They differ in population, compound, duration, vascular bed and outcome. The vascular tone overview explains the contractile side of vessel function, while barrier measurements concern passage across the lining. A trial of one cannot automatically validate the other.

The distinction between vitamin D status and vitamin D effect is equally important. A low circulating concentration, a pharmacological response to an active analogue and a response to nutritional replacement describe different relationships. Neither a positive cell result nor an increased blood concentration guarantees a clinical benefit.

The evidence hierarchy helps place these results in their proper roles: experiments can identify plausible mechanisms, and randomised human studies test particular interventions and outcomes. The justified conclusion is that vitamin D-related signalling can influence endothelial behaviour in defined models, while human vascular responses are context-dependent. These studies do not establish a supplement dose, a blood target or prevention of cardiovascular events.

Scientific sources

Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RHJ, Hordijk PL, Vervloet MG. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. Journal of the American Heart Association. 2018;7(17):e008776. DOI: 10.1161/JAHA.118.008776. PMID: 30371149. Principal barrier experiment, including supplementary kidney-function and α-Klotho results.

Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM. Ergocalciferol and Microcirculatory Function in Chronic Kidney Disease and Concomitant Vitamin D Deficiency: An Exploratory, Double Blind, Randomised Controlled Trial. PLoS ONE. 2014;9(7):e99461. DOI: 10.1371/journal.pone.0099461. PMID: 25006678. Human microcirculatory trial; its supplementary methods and study protocol inform the appraisal.

Borgi L, McMullan C, Wohlhueter A, Curhan GC, Fisher ND, Forman JP. Effect of Vitamin D on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Hypertension. 2017;30(2):124-129. DOI: 10.1093/ajh/hpw135. PMID: 28077419. Human supplementation comparison.

Correction to Borgi and colleagues: Erratum. American Journal of Hypertension. 2017;30(7):731. DOI: 10.1093/ajh/hpx030. PMID: 28472334. Replaces Figure 3; the numerical comparison discussed here is reported in the article text.

Related reading

Original sources

Source

Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability

Published in Journal of the American Heart Association (2018).

Publication details

Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RHJ, Hordijk PL, Vervloet MG. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. Journal of the American Heart Association. 2018;7(17):e008776. DOI: 10.1161/JAHA.118.008776. PMID: 30371149. Principal barrier experiment, including supplementary kidney-function and α-Klotho results.

Read more →
Source

Erratum

Published in American Journal of Hypertension (2017).

Publication details

Correction to Borgi and colleagues: Erratum. American Journal of Hypertension. 2017;30(7):731. DOI: 10.1093/ajh/hpx030. PMID: 28472334. Replaces Figure 3; the numerical comparison discussed here is reported in the article text.

Read more →